# 此超級綜合評等是基於以下評等的加權平均結果。

*biotech · news · 2026-05-14 · MarketScreener*

## Key points

- Trader 超級評等使用估值、每股盈餘修正（4 個月）及能見度評等的加權平均。
- Investor 超級綜合評等包含基本面、每股盈餘修正（1 年）、估值及能見度評等。
- Global 綜合評等需涵蓋至少五項特定綜合指標中的四項才能計算。
- Quality 綜合評等考量報酬率、獲利能力、財務報告品質及財務健康，需涵蓋至少兩項。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/aardvark-therapeutics-investigational-new-drug-application-for-ard-101-put-on-clinical-hold-by-fda-ce7f5bd2d888f322)

---

Canonical: https://newsio.io/zh-TW/n/fe9416c5-c716-4c9f-9fbf-aa496fb08ac2/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works